English 
High grade intraepithelial lesion (HSIL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00
Description
High-grade squamous intraepithelial lesion (HSIL) Epidemiology
Human papillomavirus types 16 and 18 are associated with approximately 25% of low-grade and 50% of high-grade cervical intraepithelial lesions worldwide. In the United States, HPV vaccination coverage has increased since vaccine introduction, and varies by age which has led to the decline in cases of HSIL in 15 to 24 years age-group, but no decreases have been seen in the age group from 25-39 years. The estimated numbers of U.S. CIN2+ cases were 196,000 (2016), with an estimated 76% attributable to 9-valent HPV vaccine types. In 2020, the estimated cases in US are XX million, European 5 countries (Germany, France, Italy, Spain & UK) are XX million and Japan has estimated cases of XX million. In G7, the number with High-Grade Cervical Dysplasia (HSIL) is projected to increase to XX billion in 2032.
High-grade squamous intraepithelial lesion (HSIL) Market Forecast
Market Size of High-Grade Cervical Dysplasia (HSIL) in the G7 is estimated to be XX million in 2020 and is expected to reach XX million by 2030. The market includes a surgical treatment options for High-Grade Cervical Dysplasia (HSIL) treatment.
There is a high unmet need for a new, safe non-invasive treatment especially for HSIL, to resolve cervical dysplasia and become HPV free. Any treatment that would avoid the side effects associated with procedures like LEEP would be significant patient benefit and healthcare cost savings. Several clinical trials testing immune therapies for HPV disease are currently open.The goal is to develop a combinatorial HPV immunotherapy approach that could be applied to all women with established HPV infections, that would ultimately eliminate the need for the complex and expensive screening, long-term follow-up, and surgical interventions currently employed to manage HPV disease. The identification of specific HPV antigens makes this disease an ideal model to develop antigen-specific immunotherapies for other chronic viral diseases, such as hepatitis, and ultimately, non-virus-associated cancers.
Report Highlights
- HSIL Current Market Trends
- HSIL Current & Forecasted Cases across the G7 Countries
- HSIL Market Opportunities And Sales Potential for Agents
- HSIL Patient-based Market Forecast to 2032
- HSIL Untapped Business Opportunities
- HSIL Product Positioning Vis-a-vis Competitors’ Products
- HSIL KOLs Insight
Additional information
| Price | 2-3 User License, Enterprise License, Single User License, Site License |
|---|
Table of Contents
- High-Grade Cervical Dysplasia (HSIL) Disease Background
- High-Grade Cervical Dysplasia (HSIL) Definition
- Symptoms
- Risk Factor
- Diagnosis
- Epidemiology Estimated and Forecast to 2030
- Epidemiology Research Method & Data Sources Used
- Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in the United States 2022-2032
- Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in the United States 2022-2032
- Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in Germany 2022-2032
- Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in Germany 2022-2032
- Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in France 2022-2032
- Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in France 2022-2032
- Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in Italy 2022-2032
- Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in Italy 2022-2032
- Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in Spain 2022-2032
- Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in Spain 2022-2032
- Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in the United Kingdom 2022-2032
- Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in the United Kingdom 2022-2032
- Prevalent Cases of High-Grade Cervical Dysplasia (HSIL) in Japan 2022-2032
- Treated Cases of of High-Grade Cervical Dysplasia (HSIL) in Japan 2022-2032
- Epidemiology Research Method & Data Sources Used
- Current Unmet Needs in High-Grade Cervical Dysplasia (HSIL)
- Current Treatment Paradigm
- Treatment/Prevention guidelines for High-Grade Cervical Dysplasia (HSIL)
- Regulatory Approvals/Indication and Current Benchmarks
- Emerging Therapies Chapters
- Cevira (Asieris)
- VGX-3100/CELLECTRA (Inovio)
- INTERFERON ALPHA-2B (Better Life Pharma)
- Emerging Vaccine Chapters
- Gardasil (Merck)
- HPV-16/18 vaccine (Shanghai Zerun Biotechnology Co.,Ltd)
- BLS-ILB-E710c (BioLeaders Corporation)
- GX-188E (Genexine, Inc.)
- Others
- KOLs Insight (US, EU, JP)
- Unmet Needs
- Analysis of the progresses in terms of approvals & current pipeline;
- Impact on the treatment algorithm and product positioning
- Relevance of new targets/platforms/ Therapy Uptake Share %
- Physicians Preferences for the new pharmacological agents
- What’s New in 2020
- Future Treatment Paradigm
- High-Grade Cervical Dysplasia (HSIL) Competitor Landscape and Approvals Anticipated
- Future Treatment Algorithms and Competitor Positioning
- Key Data Summary for Emerging Treatment
- Late Phase Therapies Strategic Considerations in High-Grade Cervical Dysplasia (HSIL)
- Total Market Forecast
- Key Summary Findings
- G7 total Market for High-Grade Cervical Dysplasia (HSIL) 2022-2032 (USD Million)
- G7 total Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2022-2032 (USD Million)
- Market Forecast by Country
- United States
- United States Market for High-Grade Cervical Dysplasia (HSIL) 2022-2032 (USD Million)
- United States Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for High-Grade Cervical Dysplasia (HSIL) 2022-2032 (USD Million)
- Germany Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2022-2032 (USD Million)
- France
- France Market for High-Grade Cervical Dysplasia (HSIL) 2022-2032 (USD Million)
- France Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for High-Grade Cervical Dysplasia (HSIL) 2022-2032 (USD Million)
- Italy Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for High-Grade Cervical Dysplasia (HSIL) 2022-2032 (USD Million)
- Spain Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for High-Grade Cervical Dysplasia (HSIL) 2022-2032 (USD Million)
- United Kingdom Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for High-Grade Cervical Dysplasia (HSIL) 2022-2032 (USD Million)
- Japan Market for High-Grade Cervical Dysplasia (HSIL) by Therapies 2022-2032 (USD Million)
- United States
- Key Summary Findings
- Market Drivers & Barriers
- Appendix
- Report Methodology
Sample Enquiry
Related products
-
Mitochondrial Epilepsy (MIT-E) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Mitochondrial epilepsy (MIT-E) therapeutic market is expected to increase at a significant rate during the figure time frame, 2022 to 2032. In 2022, the market is developing at a consistent rate and the market is relied upon to ascend over the projected horizon with the rise in adoption strategies by key market players. The therapy market is expected to experience high growth throughout our study period, increasing from 2018 to 2032.
-
Neuromyelitis Optica Spectrum Disorder (NMOSD) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsWe see great future treatment opportunity for the NMOSD market because of the launch of the emerging therapies like Telitacicept (RC-Pharma), Ravulizumab (Alexion Pharmaceuticals), SHR1459 (Reistone Biopharma) and others potential therapies, providing the global solution for “optic neuritis with spinal cord manifestations and other neurologic disorders associated with the serum aquaporin-4 immunoglobulin G antibodies”.
-
Obstructive Sleep Apnea (OSA) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in the number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. has mild OSA, while one out of 15 has moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to the increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2022 to 2032
-
Prader-Willi Syndrome (PWS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Prader-Willi Syndrome (PWS) market is hugely contributed by current standard of care (human growth hormone therapy) as there is no cure for PWS. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. In a PWS treatment setting, the current SoC will decline, and the novel emerging drugs will grasp the highest market shares. The sales of the emerging therapies for the treatment of PWS in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 2.1 billion by 2032.